All companies
Visit website
Aphios Pharma
OperatingAphios Pharma LLC
Technology · Founded 2018
Aphios Pharma LLC, a wholly-owned subsidiary of Aphios Corporation, is dedicated to the discovery, delivery, development and commercialization of drugs to treat Central Nervous System (CNS) and other disorders with a focus on Opioid Addiction.
Post-money valuation ⓘ
$69.0M
As of Jan 2025 · from Aphios Pharma Common Stock 3 · pre-money + amount raised, not a traded price
Total raised
$210,185
Across 6 rounds since 2018
Latest share price
$3.44
Aphios Pharma Common Stock 3 offering price
Financials
FY2016–FY2025 · from SEC filings · hover any figure for its source$0
−$12
2018
$0
−$3K
2019
$0
−$16K
2020
$0
−$30K
2021
$0
−$36K
2022
$0
−$822
2023
$0
2024
$0
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Chart shows the most recent 8 fiscal years; 2 earlier years are in the table below.
Metric
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$0
$0
-$12
-$3,255
-$15,935
-$29,635
-$36,427
-$822
$0
$0
Taxes paid
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$0
$0
$238
$1,524
$1,386
$1,284
$0
$0
$0
$0
Accounts receivable
$0
$0
$0
$42,112
$25,915
$24,642
$0
$0
$0
$0
Total assets
$0
$0
$238
$43,635
$27,301
$25,926
$0
$0
$0
$0
Short-term debt
$0
$0
$0
$400
$0
$1,620
$38,761
$39,583
$52,291
$37,469
Long-term debt
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Total liabilities
$0
$0
$0
$400
$0
$1,620
$38,761
$39,583
$52,291
$37,469
Other
Headcount
—
2
—
5
12
5
5
6
—
7
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$71.0M
Valuation cap
$69.0M
post-money
APHIOS PHARMA LLC Future Equity SAFE 2
Aphios Pharma Common Stock 3
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised — / $618KPost-money $69M
Raised $65K / $618K
Raised $97K / $1M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 6 of 8 annual reports (FY2018–FY2025)
88 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 21 filings on EDGARSource: ManualCIK 0001750795Share price $3.44
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.